Gritstone Bio Inc GRTS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GRTS is a good fit for your portfolio.
News
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
-
Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
-
Gritstone bio Announces Workforce Reduction
-
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences
-
Gritstone bio Announces Update to Comparative Phase 2b COVID-19 Clinical Trial
Trading Information
- Previous Close Price
- $2.80
- Day Range
- $2.52–2.94
- 52-Week Range
- $1.14–3.33
- Bid/Ask
- $2.68 / $2.69
- Market Cap
- $252.03 Mil
- Volume/Avg
- 2.3 Mil / 1.9 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 222.64
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Gritstone Bio Inc is a biotechnology company. The company is engaged in developing personalized cancer immunotherapies to fight multiple cancer types and infectious diseases. It is building a pipeline of Immunotherapies product candidates for patients with solid tumors, which includes GRANITE, SLATE, and CORAL, among others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 231
- Website
- https://gritstonebio.com
Comparables
Valuation
Metric
|
GRTS
|
CLDX
|
ITOS
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | 57.57 |
Price/Book Value | 4.83 | 5.45 | 0.85 |
Price/Sales | 222.64 | 294.86 | 38.73 |
Price/Cash Flow | — | — | — |
Price/Earnings
GRTS
CLDX
ITOS
Financial Strength
Metric
|
GRTS
|
CLDX
|
ITOS
|
---|---|---|---|
Quick Ratio | 2.91 | 13.69 | 13.46 |
Current Ratio | 3.20 | 13.87 | 13.76 |
Interest Coverage | −34.60 | — | — |
Quick Ratio
GRTS
CLDX
ITOS
Profitability
Metric
|
GRTS
|
CLDX
|
ITOS
|
---|---|---|---|
Return on Assets (Normalized) | −60.14% | −30.49% | −12.92% |
Return on Equity (Normalized) | −114.14% | −33.19% | −14.67% |
Return on Invested Capital (Normalized) | −67.65% | −32.85% | −18.54% |
Return on Assets
GRTS
CLDX
ITOS
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hzkgppqgh | Ppdd | $570.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qlhjtgdzj | Ygzpft | $107.8 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dryfvqww | Wbhqd | $105.6 Bil | |
MRNA
| Moderna Inc | Kqhzjymg | Grtx | $42.3 Bil | |
ARGX
| argenx SE ADR | Xylcllmbl | Hhf | $23.7 Bil | |
BNTX
| BioNTech SE ADR | Zmqwmzpt | Dng | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rzzgnnqh | Xdcnqc | $19.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vpzddvpwz | Zgghtt | $16.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Hhqgsdxwn | Gghdsd | $13.6 Bil | |
INCY
| Incyte Corp | Rhgvzhsv | Gycydnt | $12.8 Bil |